Magnetic Resonance Spectroscopy (MRS) Validation Study in Individuals With Nonalcoholic Fatty Liver Disease (NAFLD): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Magnetic Resonance Spectroscopy (MRS) Validation Study in Individuals With Nonalcoholic Fatty Liver Disease (NAFLD) (NCT00940537), a registered phase not stated study. The primary outcome is The Reproducibility of the Hepatic Triglyceride Content Measurement by MRS..

2. Clinical Question

The study is framed as a validation investigation: it asks whether an optimized MRS sequence can quantify hepatic triglyceride content and thereby support MRS as a diagnostic tool in NAFLD. Its primary endpoint is the reproducibility of the measurement, expressed as a coefficient of variation for the triglyceride signal divided by the water signal. The registry describes comparisons among a standard sequence and optimized sequences using breath-holds or free-breathing.

The clinical question is therefore about measurement performance, not about a treatment effect. The registry also lists pre- and post-prandial hepatic triglyceride content and triglyceride-to-water T2 ratios as secondary outcomes. It does not report the numerical results for these outcomes or the primary reproducibility endpoint. Consequently, the registry record alone does not establish the degree of agreement, repeatability, or diagnostic performance achieved by any sequence.

3. Trial Design

The registry identifies this as a completed MRS validation study sponsored by Washington University School of Medicine. The listed enrollment is 14. The record gives a study start of 2009-06 and a primary completion date of 2010-03. It describes two participant groups: non-diabetic, obese participants with diagnosed NAFLD and non-diabetic, obese participants with no previous diagnosis of NAFLD.

The central measurement exercise compared three 1H-Magnetic Resonance Spectroscopy sequences: a standard Siemens sequence and an optimized sequence used either with breath-holds or with free-breathing. Repeat scans were performed after the subject was briefly removed from and returned to the scanner. This repeat-scan procedure is relevant because reproducibility concerns whether a measurement remains similar when the scanning process is repeated, including the interruption and return described in the registry.

The record does not state how participants were allocated to the two groups or whether sequence order was randomized. It explicitly cautions that the study is not a randomized comparison and that the arms are not a like-for-like control comparison. The group labels should therefore be understood as descriptions of the participants, not as evidence of randomized assignment or equivalent groups. The registry does not report further details about recruitment, eligibility beyond the group descriptions, masking, sequence order, or the number of scans contributed by each participant.

The primary outcome is the reproducibility of the HTGC measurement by MRS. Two secondary outcomes are listed: pre- and post-prandial hepatic triglyceride content, and T2 ratios of triglyceride to water. The record lists three outcome measures and four analyses, but does not provide a complete statistical analysis plan or numerical outcome results. It also does not report a sample-size justification for the study itself. Any sample-size figures framed as planning illustrations are not evidence that the study was designed to those targets.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: All enrolled subjects completed the study.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as The Reproducibility of the Hepatic Triglyceride Content Measurement by MRS., measured over 6 months.

The primary endpoint is described as the reproducibility of the hepatic triglyceride content measurement by MRS. The reported measure is a coefficient of variation for the triglyceride signal divided by the water signal, with the outcome parameter identified as a mean and dispersion identified as a standard error. The registry gives a timeframe of 6 months and describes repeat scans after the participant was briefly removed from and returned to the scanner.

In general, reproducibility concerns the consistency of repeated measurements under the conditions being studied. A coefficient of variation expresses variability relative to the measurement scale, allowing measurement repeatability to be considered in relation to the size of the measured signal. It is distinct from a direct comparison of average HTGC between the NAFLD and Non-NAFLD groups. The standard error describes the precision of an estimated mean; it is not itself the variability among individual scan measurements.

This endpoint is relevant to a validation study because measurement consistency is one element of whether a method can be useful for quantifying a biological quantity. The registry description suggests that the scan sequence, breathing condition, and repeat-scan procedure are central to the comparison. However, it does not report the coefficient-of-variation estimates, their standard errors, or uncertainty intervals. Without those results, the size and precision of any observed reproducibility differences are not reported in the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The statistical interpretation begins with the distinction between a measurement question and a treatment-comparison question. This study's stated primary endpoint concerns reproducibility of HTGC measurement by MRS. The registry describes scans with three sequences and repeat scans following a brief removal from and return to the scanner. It does not describe random assignment to a treatment or intervention. The record explicitly says allocation is not stated and that the arms are not a like-for-like control comparison. The study should therefore be read as a measurement validation investigation rather than as a randomized efficacy comparison.

What does a coefficient of variation describe?

In general, a coefficient of variation expresses the amount of variation in measurements relative to the scale of those measurements. This can help describe repeatability when the magnitude of a measurement matters to how its variability is interpreted. The endpoint description identifies the measured signal as triglyceride divided by water and identifies the outcome parameter as a mean. It lists standard error as the dispersion measure. The registry does not give the coefficient-of-variation estimates or standard errors, so the magnitude and precision of the endpoint cannot be assessed from the record.

Standard error and standard deviation answer different questions. In general, standard deviation describes spread among individual observations, whereas standard error describes precision of an estimated statistic, such as a mean. The registry lists standard error for dispersion, but does not provide scan-level observations or enough detail to determine exactly how the reported analysis handled repeated measurements within participants. It would be inappropriate to infer those details from the endpoint label alone.

Why does repeat scanning matter?

In general, repeating a measurement helps assess whether a measurement procedure produces consistent values under repeated use. The registry says participants were briefly removed from and returned to the scanner between repeat scans. That procedure defines an aspect of the conditions under which reproducibility was to be assessed. It does not establish whether every participant completed every repeat scan, whether the same sequence order was used for all participants, or how repeated observations were incorporated into the analysis. Those protocol and analysis details are not reported in the registry record.

The sequence comparison includes a standard Siemens sequence and an optimized sequence with either breath-holds or free-breathing. These are three sequence conditions named in the study description. The registry does not report numerical estimates for each condition or a statistical test comparing them. Without those estimates and their uncertainty, there is no basis in the posted record for ranking the sequences or judging whether any differences are precise.

How should uncertainty be understood?

In general, a confidence interval describes a range of values compatible with the data and an estimation procedure, reflecting uncertainty in the estimate. The registry does not report confidence intervals for the primary endpoint. The listed standard error alone, without a numerical value or further results, does not permit an assessment of precision. A result can be described as a mean with a standard error in the outcome specification, but no actual mean or standard error is reported in the registry record.

The registry's sample-size assumptions describe planning illustrations based on the observed effect, not the trial's design. The stated assumptions are a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; the effect to detect is described as a stated fraction of the observed effect. Such calculations are prospective planning exercises. They are not observed power, do not show how the study was actually planned, and do not recover missing outcome results. The registry does not report its own sample-size justification. Any numerical planning outputs do not change that distinction.

What can the analysis counts tell us?

The record lists three outcome measures and four analyses. These counts indicate that multiple outcome or analysis entries exist in the registry, but they do not reveal which analyses were primary, prespecified, adjusted, or exploratory. They also do not establish that every planned analysis is represented. The primary outcome description and the two named secondary outcomes identify the measurement topics, but the record does not give a full statistical analysis plan, specific model forms, hypothesis tests, covariate adjustments, or multiplicity procedures.

In general, over-dispersion means that observed variation is greater than a model assumes. When present, it can affect uncertainty estimates and tests if a model does not account for the extra variation. The registry does not identify an over-dispersion issue or a model for which this concern is relevant, so no claim about its presence or handling can be made for this study. Likewise, the record does not report the statistical method used to account for dependence among repeat scans from the same participant.

Overall, the methods information supports an explanation of the measurement question and the stated planning assumptions, but not a reconstruction of the analysis. Outcome estimates, uncertainty intervals, model details, and analysis-population definitions are not reported in the registry record. The numerical evidence needed to judge reproducibility is therefore unavailable in the posted registry information.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists three outcome measures and four analyses. It identifies the primary outcome as reproducibility of the HTGC measurement by MRS and names two secondary outcomes: pre- and post-prandial hepatic triglyceride content, and T2 ratios of triglyceride to water. The record does not explain how the four analyses map to these outcomes, whether there were additional comparisons within an outcome, or which analyses were prespecified.

Multiplicity arises in general when several outcomes, comparisons, or analyses are considered, because the chance of finding a seemingly notable result can change as the number of analyses increases. The registry record does not report whether any multiplicity adjustment was planned or used. It also does not report an analysis hierarchy or a strategy for interpreting secondary outcomes. The number of listed outcomes and analyses alone does not establish that a multiplicity problem occurred, nor does it show how one was handled.

Missing-data methods and analysis populations are not reported in the registry record. The listed enrollment is 14, but the record does not specify how many participants contributed data to each endpoint, whether any scans or outcomes were missing, how missing measurements were handled, or whether any participants were excluded from analyses. It does not describe an intention-to-treat, per-protocol, or other analysis population. The registry also does not give information about withdrawals or reasons for unavailable measurements.

These omissions limit interpretation of precision and representativeness. Without endpoint-specific participant counts and missing-data methods, the posted record does not show whether the reported analyses, if any, included all enrolled participants or how incomplete repeated measurements were handled.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 2% reporting threshold.

The registry reports serious adverse event counts for the NAFLD and Non-NAFLD groups. For serious events, 5 participants were listed as at risk in the NAFLD group and 9 in the Non-NAFLD group; the number affected was 0 in each group. For other adverse events, the corresponding at-risk counts were 5 and 9, and the numbers affected were also 0 in both groups.

These are the counts posted for the listed groups and event categories. They should not be interpreted as proof that no adverse events of any kind occurred, or as a comparison of safety between randomized treatments. The registry says allocation was not stated and cautions that the arms are not a like-for-like control comparison. The death fields are not reported in the registry record. The record does not provide additional detail about how adverse events were collected, how long participants were monitored, or the criteria used to classify events.

In general, zero events in a small group do not establish that an event is impossible or that a procedure has no risk. These figures are counts, not estimates of comparative safety. No medical conclusion should be drawn from them beyond the specific event counts and at-risk group sizes listed in the registry.

12. What the Result Does, and Does Not, Mean

The study addresses a focused statistical question: how consistently MRS sequences measure the triglyceride-to-water signal when scans are repeated under the stated procedure. This is a measurement-validation question. It differs from asking whether a treatment changes a health outcome, and it differs from demonstrating that an imaging method correctly diagnoses every participant. The stated study purpose is to assess an optimized MRS sequence for quantifying HTGC and to enhance MRS as a diagnostic tool in NAFLD.

The registry record does not report the primary endpoint estimates, standard errors, confidence intervals, or secondary outcome values. It therefore does not show how reproducible the measurements were, whether the optimized sequence differed from the standard sequence, or whether the breathing conditions changed the results. The registry also does not report diagnostic accuracy measures. The study's stated purpose cannot stand in for those empirical results.

The two participant groups are described by NAFLD diagnosis status, but allocation is not stated and the registry warns that the groups are not a like-for-like control comparison. The record consequently does not support a causal interpretation of differences between the group descriptions. Nor can the enrollment count alone establish that the study had adequate precision for any particular comparison; a study-specific sample-size justification is not reported.

In general, a validation result is most informative when the measurement estimate is presented with its uncertainty and with sufficient detail about the measurement procedure and analysis. Here, the registry supplies a description of the endpoint and repeat-scan procedure, but not the numerical outcome information needed to characterize the observed performance. The record supports understanding what the investigators set out to measure, not a conclusion about what their measurements demonstrated.

13. Why This Trial Matters Statistically

This study is statistically notable for focusing on the measurement process itself. In clinical research, an outcome is only as interpretable as the method used to measure it. Examining repeatability can help characterize whether a measurement procedure gives consistent values under specified conditions. The registry's repeat-scan description, including briefly removing and returning participants to the scanner, identifies a concrete part of the measurement process under investigation.

The comparison of a standard Siemens sequence with optimized breath-hold and free-breathing sequences also makes the measurement conditions explicit. Distinguishing sequence and breathing conditions matters because a reproducibility estimate applies to the procedure that generated it; it should not automatically be generalized to different procedures or settings. The registry does not report the numerical results or enough protocol detail to determine how broadly any findings might apply.

The study also illustrates why outcome definitions and results need to be read separately. Naming a coefficient of variation, a mean, and a standard error describes the intended statistical summary, but does not convey the estimated repeatability without the corresponding values. Likewise, recording secondary outcomes does not reveal their findings. The absence of reported outcome values sharply limits what can be learned from the registry record, despite the clear statement of the study's measurement question.

Finally, the record's warning that the groups are not like-for-like controls is important. Group labels can describe participant characteristics without creating a randomized comparison. Keeping that distinction clear helps prevent an observational group contrast from being interpreted as a causal effect. The study's statistical importance lies in its validation aim and in the need for transparent reporting of measurement estimates, their uncertainty, and the conditions under which they were obtained.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The central limitation for interpretation is that numerical results for the primary endpoint are not reported in the registry record. The coefficient-of-variation estimates and their standard errors are absent, as are uncertainty intervals and the results for the listed secondary outcomes. This prevents assessment of the size and precision of the reproducibility findings or comparison among the three sequences.

Enrollment was 14, and the adverse-event record lists 5 participants at risk in the NAFLD group and 9 in the Non-NAFLD group. The registry does not say how many participants contributed measurements to each outcome, or whether repeat scans were missing. It does not describe missing-data handling, analysis populations, withdrawals, or exclusions. This makes it impossible to establish from the registry record how complete the endpoint data were.

The allocation method is not stated, and the registry explicitly says this is not a randomized comparison and the arms are not like-for-like controls. The participant groups differ by their NAFLD diagnosis descriptions, so group differences cannot be interpreted as causal effects based on the information recorded. The registry also does not report sequence order, masking, or the statistical handling of repeated scans.

The record lists three outcome measures and four analyses but does not describe a complete analysis plan or multiplicity approach. It also does not report a study-specific sample-size justification. These omissions make it difficult to assess prespecification and the intended precision. The completed status and stated study purpose do not resolve these limitations or supply the missing outcome results.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Magnetic Resonance Spectroscopy (MRS) Validation Study in Individuals With Nonalcoholic Fatty Liver Disease (NAFLD) — NCT00940537.
• Registry record last updated 2018-06-15; status last verified 2018-06.
• Results first posted 2010-05-13.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT00940537 is a completed MRS validation study sponsored by Washington University School of Medicine, with enrollment of 14 and dates listed as 2009-06 to 2010-03 for study start and primary completion. It concerns non-diabetic, obese participants with diagnosed NAFLD and non-diabetic, obese participants with no previous NAFLD diagnosis.

The primary outcome concerns reproducibility of hepatic triglyceride content measurement by MRS. The study description compares a standard Siemens sequence with optimized breath-hold and free-breathing sequences and describes repeat scans after participants were briefly removed from and returned to the scanner. Secondary outcomes concern pre- and post-prandial HTGC and T2 ratios of triglyceride to water.

The registry does not report the numerical primary or secondary outcome results, a full statistical analysis plan, missing-data methods, or a study-specific sample-size justification. It states that allocation is not given and that the groups are not a like-for-like control comparison.